Show simple item record

dc.contributor.authorMedina Villaamil, Vanessa
dc.contributor.authorÁlvarez García, A.
dc.contributor.authorAparicio Gallego, Guadalupe
dc.contributor.authorDíaz-Prado, Silvia
dc.contributor.authorRivas López, A.
dc.contributor.authorSantamarina, Isabel
dc.contributor.authorValladares-Ayerbes, Manuel
dc.contributor.authorAntón-Aparicio, Luis M.
dc.date.accessioned2015-06-16T08:33:32Z
dc.date.available2015-06-16T08:33:32Z
dc.date.issued2011-03-22
dc.identifier.citationMedina Villaamil V, Álvarez García A, Aparicio Gallego G, Díaz Prado S, Rivas López A, Santamarina Caínzos I, et al. Tissue array analysis for the differentiation of gliosis from gliomas. Mol Med Rep. 2011;4:451-457.es_ES
dc.identifier.urihttp://hdl.handle.net/2183/14681
dc.description.abstract[Abstract] The aim of this study was to provide a methodology to make a clear distinction between malignant tumors and morphologically similar benign processes, by examining the expression of EGFR, VEGF, HIF1-α, survivin, Bcl-2 and p53 proteins. Four groups of patient samples were studied: group 1, low-grade astrocytomas (WHO grades I-II) (n=6); group 2, peripheral area of high-grade astrocytomas (WHO grades III-IV) (n=5); group 3, gliomatosis cerebri (n=11); and group 4, reactive gliosis (n=6). Tissue arrays (TAs) were designed to study apoptosis, angiogenesis and invasion-related proteins by immunohistochemistry (IHC). By means of non-parametric analysis (Mann-Whitney U test), EGFR staining was shown to be significantly lower in reactive gliosis than in the low- and high-grade astrocytomas (p=0.015 and p=0.030, respectively); Bcl-2 immunoreactivity was significantly higher in the gliomatosis cerebri samples than in the reactive processes (p=0.005); and finally, Bcl-2 presented significantly lower expression levels in reactive gliosis compared to the peripheral areas of high-grade astrocytomas (p=0.004). The results indicate that Bcl-2 and EGFR may be useful in conducting differential diagnosis between the above groups, while the expression of the remaining antibodies does not appear to aid in distinguishing between the samples analyzed. The use of TAs to identify the protein expression profiles of biological markers related to different pathways was verified, and its potential as a discriminatory technique for everyday pathology procedures was demonstrated.es_ES
dc.language.isoenges_ES
dc.publisherSpandidoses_ES
dc.relation.urihttp://dx.doi.org/10.3892/mmr.2011.462es_ES
dc.subjectAstrocytomases_ES
dc.subjectBcl-2es_ES
dc.subjectEpidermal growth factor receptores_ES
dc.subjectGliomastosis carebries_ES
dc.subjectReactive glosises_ES
dc.subjectSurvivines_ES
dc.subjectTissue arrayes_ES
dc.titleTissue array analysis for the differentiation of gliosis from gliomases_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record